ArticleRegional anesthesia and pain medicine2026
Treatment gaps for opioid use disorder among commercially insured US surgical patients, 2016-2022.
Article in Regional anesthesia and pain medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDespite clear evidence of treatment gaps for opioid use disorder (OUD) among the general population, diagnosis and treatment patterns among surgical patients remain poorly characterized. This study aimed to examine national trends in OUD diagnosis and exposure to treatment with medications for opioid use disorder (MOUD) among US surgical patients.
methodsThis population-based cohort study used the Merative MarketScan Commercial Database from July 1, 2016 to December 31, 2022. US adults aged 18-64 years undergoing inpatient or outpatient surgery were included. OUD was identified using International Classification of Disease, 10th Revision codes. MOUD receipt was defined as 1+pharmacy or medical claims for buprenorphine, methadone, or naltrexone within 180 days before surgery. Multivariate logistic regression assessed trends in OUD and MOUD receipt, adjusting for patient, surgical, and clinical variables.
resultsAmong 5 341 768 surgical patients (62.5% female), 31 094 (0.58%) had an OUD diagnosis. The prevalence of OUD declined from 0.71% in 2016 to 0.50% in 2022. Among patients with OUD, the proportion receiving MOUD in the 6 months before surgery increased from 17.8% to 32.6% over the study period. The corresponding treatment gap in MOUD receipt decreased from 82.2% in 2016 to 67.4% in 2022.
conclusionsIn this national cohort of commercially insured surgical patients, most individuals diagnosed with OUD did not receive evidence-based treatment before surgery, despite modest improvements over time. These findings highlight a persistent treatment gap and suggest missed opportunities to improve perioperative care and outcomes for patients with OUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.